RIBOMIC announces positive top-line results from phase 1/2a trial of rbm-007 in wet AMD
SUSHI study achieved the primary endpoint of safety and tolerability, and also demonstrated efficacy trends in favor of RBM-007. Subjects recruited for the SUSHI Study had wet AMD